



## FINANCIAL TEAR SHEET

### CORPORATE PROFILE

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

### STOCK MARKET DATA

#### ERYP.PA (Common Stock)

<b>Exchange</b>	Paris (Euro)
<b>Price</b>	€9.11
<b>Change (%)</b>	▲ 0.26 (2.94%)
<b>Volume</b>	39,940
<b>52 Week Low</b>	€8.61
<b>Market Cap</b>	€79,554,423
<b>Rolling EPS</b>	-2.95
<b>PE Ratio</b>	0

**Shares Outstanding** 8,732,648

Data as of 08/17/18 5:35 p.m. ET

#### ERYP (Common Stock)

<b>Exchange</b>	NASDAQ GS (US Dollar)
<b>Price</b>	\$10.26
<b>Change (%)</b>	▲ 0.54 (5.56%)
<b>Volume</b>	494
<b>52 Week Low</b>	\$9.72
<b>Market Cap</b>	\$
<b>Rolling EPS</b>	0.00
<b>PE Ratio</b>	0

**Shares Outstanding**

Data as of 08/17/18 3:18 p.m. ET

## STOCK MARKET DATA



Data provided by Nasdaq. Minimum 15 minutes delayed.

## RECENT NEWS & EVENTS

17-Jul-2018

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018

24-Jun-2018

ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia

20-Jun-2018

ERYTECH to Present at JMP Securities Life Science Conference

**Date**

**Title**

09/11/18 2:30 p.m. CET **Erytech Pharma Second Quarter 2018 Conference Call and Webcast**

11/13/18 2:30 p.m. CET **Erytech Pharma Third Quarter 2018 Conference Call and Webcast**

## SEC FILINGS

Filing Date	Form
07/19/18	SC 13D
07/17/18	6-K
07/02/18	SC 13D/A
07/02/18	SC 13G/A

## CORPORATE GOVERNANCE

Gil Beyen, MBA Chairman and Chief Executive Officer

Eric Soyer, MBA Chief Financial Officer & Chief Operating Officer

Yann Godfrin, PhD Chief Scientific Officer

Iman El-Hariry, MD, PhD Chief Medical Officer

Jérôme Bailly, Pharm.D. Director of Pharmaceutical Operations and Qualified Person